V. Baryash
Belarusian State Medical University
7 Papers
21 Citations
V. Baryash is an academic researcher from Belarusian State Medical University. The author has contributed to research in topics: Trastuzumab & Breast cancer. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).
Justin Stebbing,Yauheni Valerievich Baranau,V. Baryash,Alexey Manikhas,Vladimir Moiseyenko,Giorgi Dzagnidze,Edvard Javrid,Dmytro Boliukh,Daniil Stroyakovskiy,Joanna Pikiel,Alexandru Eniu,Dmitry Komov,Zakaria Zautashvili,Gabriela Morar-Bolba,Rubi Khaw Li,Igor Lifirenko,Andriy Rusyn,Sang Joon Lee,Sung Young Lee,Francisco J. Esteva +19 more
TL;DR: The similarity of C and trastuzumab in efficacy and safety for HER2+ EBC was similar and the 95% CIs for the risk ratio estimate were within the equivalence margin.
14
152PDDouble-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
Francisco J. Esteva,Yauheni Valerievich Baranau,V. Baryash,Alexey Manikhas,Vladimir Moiseyenko,Giorgi Dzagnidze,Edvard Zhavrid,Dmytro Boliukh,Daniil Stroyakovskiy,Joanna Pikiel,Alexandru Eniu,Dmitry Komov,Z. Zautashvili,G. Morar-Bolba,R. K. Li,I. Lifirenko,A. Rusyn,Sang Joon Lee,S. Yu,Justin Stebbing +19 more
7
3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Justin Stebbing,Yauheni Valerievich Baranau,V. Baryash,Alexey Manikhas,Vladimir Moiseyenko,Giorgi Dzagnidze,Edvard Zhavrid,Dmytro Boliukh,Daniil Stroyakovskiy,Joanna Pikiel,Alexandru Eniu,Dmitry Komov,Sang Joon Lee,M.J. Kim,S.-B. Kim,S. Park,J.H. Bae,Francisco J. Esteva +17 more
TL;DR: Overall, the rates of disease-free survival (DFS) and overall survival (OS) were similar between CT-P6 and RTZ in both PPS and ITT set and the number of DFS events and OS events were comparable inITT set.
5
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
Justin Stebbing,Yauheni Valerievich Baranau,V. Baryash,Vladimir Moiseyenko,Dmytro Boliukh,N. Antone,Alexey Manikhas,A. Chornobai,Taehong Park,Eric Hyungseok Baek,Jaeyong Lee,Jiin Choi,Nahyun Kim,K. Ahn,Sang Joon Lee,Sung-Han Kim +15 more
TL;DR: The CT-P6 3.2 study as discussed by the authors demonstrated equivalent efficacy and comparable safety between CTP6 and reference trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer after up to 3 years' follow-up.
185P Long-term efficacy of trastuzumab biosimilar CT-P6 in patients with HER2-positive early breast cancer: 6-year survival analysis of phase III study results
Justin Stebbing,Yauheni Valerievich Baranau,V. Baryash,Vladimir Moiseyenko,Dmytro Boliukh,N. Antone,Aleksei Manikhas,A. Chornobai,Sh Kim Shin-Hyun Kim,K. Ahn,Taejung Park,E. Baek,S.E. Park,S. Lee,In-Suk Chang,Jysoo Lee,Jieun Choi +16 more
TL;DR: The equivalence between CT-P6 and RTZ in clinical efficacy and safety has been demonstrated in studies including an international phase III randomized study (CT-P 6 3.2) as mentioned in this paper .